• CareDx recently reported that a large Kidney Allograft Outcomes AlloSure Registry study, published in the Journal of the American Society of Nephrology, linked elevated AlloSure Kidney donor-derived cell-free DNA levels with higher risks of allograft dysfunction and graft loss in kidney transplant recipients over three years.
• These findings, reinforced by more than 30 abstracts and 9 oral presentations at the American Transplant Congress 2026, highlight AlloSure’s growing role as a noninvasive clinical endpoint for long-term transplant risk assessment and treatment monitoring.
• We’ll now examine how this new evidence for AlloSure’s prognostic value could influence CareDx’s investment narrative and long-term growth assumptions.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

CareDx Investment Narrative Recap

To own CareDx, you need to believe that transplant-focused diagnostics like AlloSure can become embedded in long-term care pathways, and that reimbursement remains supportive enough to monetize that role. The new KOAR data and ATC presentations strengthen AlloSure’s clinical case, but they do not directly change the near term reimbursement overhang from potential bundled payments or frequency limits, which still looks like the key catalyst and the biggest risk in the story.

The KOAR study, published in the Journal of the American Society of Nephrology, is especially relevant here because it ties elevated AlloSure Kidney dd-cfDNA levels to higher graft risk in over 1,200 patients across 56 centers. Together with more than 30 CareDx-supported abstracts and 9 oral talks at ATC 2026, this reinforces the company’s push to position AlloSure as a clinical endpoint, which could matter if payers increasingly favor tests with clear, long-term outcome data.

Yet while this clinical progress is encouraging, investors should be aware that...

CareDx's narrative projects $524.6 million revenue and $49.9 million earnings by 2029. This requires 8.3% yearly revenue growth and a $58.1 million earnings increase from -$8.2 million today.

Uncover how CareDx's forecasts yield a $25.80 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$505 million by 2028, but if payer pushback on pricing and new bundled reimbursement rules tighten further in light of evolving evidence, that more bullish path could look very different from today’s consensus.

Explore 3 other fair value estimates on CareDx - why the stock might be worth just $25.80!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CareDx research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free CareDx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CareDx's overall financial health at a glance.

No Opportunity In CareDx?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.